



Abgenix Names H. David Miller Vice President, Information Technology

FREMONT, Calif., September 24 , 2001 – Abgenix, Inc. (Nasdaq: ABGX) announced today the appointment of H. David Miller to the newly created position of vice president, information technology. Mr. Miller will report to Raymond Withy, Ph.D., Abgenix's president and chief operating officer.

Mr. Miller brings over 20 years of business and information technology management experience in rapidly expanding companies in the computer and software-related industry, as well as in the medical device industry. Mr. Miller comes to Abgenix from Somnus Medical Technologies, where he was responsible for the company's information systems, networks and telecommunications infrastructure. Prior to Somnus, he was at Heartport, Inc., where he developed and implemented the information technology and systems to accommodate the company's rapid growth. His extensive experience includes executive level information systems positions at Taligent, Cognos, DCA and MDS Qantel. Mr. Miller received an M.B.A from Stanford Graduate School of Business and a B.A. in Economics from Stanford University.

Dr. Withy said, "We are pleased to have an information technology executive with David's experience join a growing company like Abgenix. He will play a valuable role in developing and executing near and long-term strategies that will integrate our information technology programs with our business plan."

Abgenix is a biopharmaceutical company focused on the development and commercialization of human monoclonal antibody therapies for a variety of diseases. The company's antibody technology platform, which includes XenoMax™ technology, enables the rapid generation and selection of high affinity, fully human antibody product candidates to disease targets appropriate for antibody therapy. Abgenix leverages its leadership position in human antibody technology by building a large and diversified product portfolio through the establishment of licensing arrangements with multiple pharmaceutical, biotechnology and genomics companies and through the development of its own internal proprietary products. For more information on Abgenix, visit the company's website at www.abgenix.com.

Statements made in this press release about Abgenix's technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix's patent portfolio. Please see Abgenix's public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix.

###